aspect biosystems clinical trial:Aspect Biosystems
Aspect Biosystems
Ourtransformativeplatformtechnologycombinesourproprietarybioprintingtechnology,therapeuticcells,biomaterials,andcomputationaldesign.。其他文章還包含有:「AspectBiosystemsEntersCollaborationwithMcMaster...」、「GovernmentsofCanadaandBritishColumbiajoinforces...」、「AspectBiosystemsAnnounces$200MillionPartnership...」、「3Dprintinglivingtissuetotreatdiabetesisclosertoclinicaltrials」、「AspectB...
查看更多 離開網站Aspect Biosystems Enters Collaboration with McMaster ...
https://www.aspectbiosystems.c
RX1 3D Bioprinter will be used to investigate novel disease mechanisms to enable the discovery of therapies for patients with chronic lung ...
Governments of Canada and British Columbia join forces ...
https://www.canada.ca
$200 million project will enable manufacturing of cutting-edge bioprinted tissue therapeutics and advance a global leading technology platform in Canada.
Aspect Biosystems Announces $200 Million Partnership ...
https://lifesciencesbc.ca
Aspect Biosystems announced that it has received a $72.75 million investment from the Governments of Canada and British Columbia.
3D printing living tissue to treat diabetes is closer to clinical trials
https://vet.ucalgary.ca
Aspect Biosystem is working to advance its bioprinted therapeutic program towards clinical evaluation and, “ultimately, introducing a ...
Aspect Biosystems and Novo Nordisk enter partnership to ...
https://www.novonordisk.ca
The collaboration will initially focus on developing bioprinted tissue therapeutics designed to maintain normal blood glucose levels without the ...
Aspect wins $72.75m from Canadian government for ...
https://www.pharmaceutical-tec
Canadian biotech Aspect Biosystems has received a $72.75m government investment to advance its proprietary bioprinting technology.
Aspect Biosystems
https://radical.vc
Aspect Biosystems is building a new class of regenerative medicine with a full-stack tissue therapeutic platform.
Breakthrough T1D Collaboration Leads to Next
https://www.breakthrought1d.or
Aspect Biosystems and Novo Nordisk announced a partnership to expand the development a new class of treatments for diabetes and obesity.